August 2022

27 Aug Ripretinib Exhibits Better Tolerability Profile than Sunitinib in Advanced GIST Tumors

In patients with advanced GIST who progressed on or were intolerant to first-line treatment with imatinib, ripretinib, a switch-control TKI, showed comparable median PFS as sunitinib, suggesting that ripretinib is active as second-line therapy for GIST. Additionally, ORR for patients receiving ripretinib in the KIT exon 11 population was higher compared with patients receiving sunitinib. Ripretinib demonstrated a more favorable safety profile and better responses on PRO measures than sunitinib. (Ref: Bauer S et al. J Clin Oncol. Aug 10, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6969173938740310016

20 Aug Poziotinib Shows Clinical Benefit in EGFR Exon 20–Mutant NSCLC, Efficacy Dependent on Insertion Location.

In 50 patients with advanced EGFR exon 20-mutant NSCLC, treatment with poziotinib showed confirmed ORRs of 31% by blinded independent review, with a median PFS of 5.5 months. Preclinical studies, in silico modeling, and molecular dynamics simulations showed that the poziotinib sensitivity was highly dependent on the insertion location, with near-loop insertions (ORR: 46%) being more sensitive than far-loop insertions (ORR: 0%). Putative mechanisms of acquired resistance to poziotinib included EGFR T790M, MET amplifications, and epithelial-to-mesenchymal transition (EMT). (Ref: Elamin YY et al. Cancer Cell. July 2022)
#oncologyresearch #clinicaldevelopment #cancertreatment #drugdevelopment #MIC

https://www.linkedin.com/feed/update/urn:li:activity:6966803202742579200

13 Aug Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

In patients with recurrent mismatch repair proficient (MMRP) Endometrial Cancer, treatment with talazoparib and avelumab showed 11.4 % confirmed ORR and 22.9 % PFS at 6 months. Patients with homologous recombination repair (HRR) alterations and/or a platinum-free interval (PFI) of ≥6 months were more likely to derive clinical benefit compared with non–HRR-altered tumors and/or PFI ≤6 months and exhibited better PFS.                          (Ref: Konstantinopoulos PA et al. JAMA Oncol. July 28, 2022.)

#oncologyresearch #clinicaldevelopment #cancerresearch

https://www.linkedin.com/feed/update/urn:li:activity:6964212547470155777

08 Aug Pembrolizumab plus chemotherapy extends survival in triple-negative breast cancer

In patients with previously untreated locally advanced or metastatic TNBC, the addition of pembrolizumab to chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine–carboplatin) resulted in significantly longer overall survival than chemotherapy alone in the CPS-10 subgroup (PD-L1 expression scores of ≥ 10). No new safety signals emerged. (Ref: Cortes J et al. N Engl J Med. July 21, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6962392637601402880